Foresite Capital Management V, LLC Diversified Active

Name: Foresite Capital Management V, LLC Q2 2021 13F Filing | 13F Explorer
Creator: Foresite Capital Management V, LLC
Published: 2021-08-16

Location: West Hollywood, CA

CIK: 0001792206 · Show all filings

Period: Q2 2021 (← Previous) (Next →)

Filing Date: Aug 16, 2021

Total Value: $254M (100.0% shares, 0.0% debt)

Holdings (17)

CGEM Cullinan Oncology, Inc. 27.7%

Value $70.33M Shares 2,731,410 Est. Cost $40.60 Unrealized -24.2%

QSI Quantum-Si Incorporated 11.3%

Value $28.71M Shares 2,342,061 Est. Cost $10.48 Unrealized 0.0%

ACRS Aclaris Therapeutics, Inc. 8.7%

Value $22.09M Shares 1,258,243 Est. Cost $19.56 Unrealized +16.2%

— Kinnate Biopharma Inc. 8.0%

Value $20.37M Shares 875,001 Est. Cost $39.78 Unrealized —

— Gemini Therapeutics, Inc. 6.2%

Value $15.76M Shares 2,435,125 Est. Cost $13.55 Unrealized —

RLAY Relay Therapeutics, Inc. 5.8%

Value $14.64M Shares 400,000 Est. Cost $45.21 Unrealized -27.1%

ALXO ALX Oncology Holdings Inc. 5.0%

Value $12.64M Shares 231,200 Est. Cost $60.15 Unrealized -0.5%

NRIX Nurix Therapeutics, Inc. 4.7%

Value $11.98M Shares 451,522 Est. Cost $33.14 Unrealized -11.4%

HIMS Hims & Hers Health, Inc. 4.5%

Value $11.51M Shares 1,056,922 Est. Cost $16.76 Unrealized -29.1%

— Population Health Investment Co., Inc. 3.8%

Value $9.744M Shares 960,000 Est. Cost $10.45 Unrealized —

— 23andMe Holding Co. 3.2%

Value $8.183M Shares 700,000 Est. Cost $11.69 Unrealized —

PHVS Pharvaris N.V. 2.7%

Value $6.784M Shares 364,142 Est. Cost $31.46 Unrealized -27.9%

— FS Development Corp. II 2.4%

Value $6.013M Shares 602,500 Est. Cost $9.96 Unrealized —

— Research Alliance Corp. II 2.0%

Value $5.07M Shares 500,000 Est. Cost $10.25 Unrealized —

— BCTG Acquisition Corp. 1.8%

Value $4.552M Shares 400,000 Est. Cost $11.44 Unrealized —

— Lucira Health, Inc. 1.3%

Value $3.22M Shares 485,000 Est. Cost $12.10 Unrealized —

MLTX Helix Acquisition Corp. 1.0%

Value $2.588M Shares 250,000 Est. Cost $11.37 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CGEM	Cullinan Oncology, Inc.	2,731,410	$70.33M	27.7%	$40.60	-24.2%	COM	230031106
QSI	Quantum-Si Incorporated	2,342,061	$28.71M	11.3%	$10.48	0.0%	COM CL A	74765K105
ACRS	Aclaris Therapeutics, Inc.	1,258,243	$22.09M	8.7%	$19.56	+16.2%	COM	00461U105
—	Kinnate Biopharma Inc.	875,001	$20.37M	8.0%	$39.78	—	COM	49705R105
—	Gemini Therapeutics, Inc.	2,435,125	$15.76M	6.2%	$13.55	—	COM	36870G105
RLAY	Relay Therapeutics, Inc.	400,000	$14.64M	5.8%	$45.21	-27.1%	COM	75943R102
ALXO	ALX Oncology Holdings Inc.	231,200	$12.64M	5.0%	$60.15	-0.5%	COM	00166B105
NRIX	Nurix Therapeutics, Inc.	451,522	$11.98M	4.7%	$33.14	-11.4%	COM	67080M103
HIMS	Hims & Hers Health, Inc.	1,056,922	$11.51M	4.5%	$16.76	-29.1%	COM CL A	433000106
—	Population Health Investment Co., Inc.	960,000	$9.744M	3.8%	$10.45	—	UNIT	G71716123
—	23andMe Holding Co.	700,000	$8.183M	3.2%	$11.69	—	COM CL A	90138Q108
PHVS	Pharvaris N.V.	364,142	$6.784M	2.7%	$31.46	-27.9%	COM	N69605108
—	FS Development Corp. II	602,500	$6.013M	2.4%	$9.96	—	COM CL A	30318F100
—	Research Alliance Corp. II	500,000	$5.07M	2.0%	$10.25	—	COM CL A	760873109
—	BCTG Acquisition Corp.	400,000	$4.552M	1.8%	$11.44	—	COM	05492W103
—	Lucira Health, Inc.	485,000	$3.22M	1.3%	$12.10	—	COM	54948U105
MLTX	Helix Acquisition Corp.	250,000	$2.588M	1.0%	$11.37	—	COM CL A	G4444C102